Anticoagulants Market is Ready to Pick $43.4 Bn by 2025

The Global Anticoagulants Market was estimated at $24.2 billion in the year 2017 and is expected to hit $43.4 billion by 2025, registering a CAGR of 7.5% during the forecast period.

The report provides a detailed analysis of key market segments, market scope, market dynamics, market size & forecast, market trends and so on. Increase in the number of geriatric population and rise in the frequency of medical conditions like atrial fibrillation, venous thromboembolism, stroke and obesity have contributed to the growth of the sector. However, the high price of NOACs and the comparatively low demand in under developed countries have deterred the growth to certain extent. On the other hand, the growing demand for NOACs and immense growth prospects in the emerging markets have paved the way for new opportunities in the sector.

Get the Sample Report @ https://www.alliedmarketresearch.com/request-sample/1673

Drug class, application, Route of administration and region are the four segments global anticoagulants market is categorized on. Based on drug class, the anticoagulants market is characterized as vitamin K antagonist, heparin and LMWH, NOACs and others. Then, based on route of administration, the market is classified as injectable anticoagulant and oral anticoagulant. The application markets are labelled as deep vein thrombosis stroke, pulmonary embolism, heart attack and others. Finally, region wise, the market is segmented across LAMEA, Asia-pacific, Europe and North America.

In terms of revenue, currently, NOAC’S segment is the largest slice in the anticoagulants market and is expected to maintain the dominance throughout the forecast period. Application wise, the segment of the atrial fibrillation & heart attack is the highest contributor of revenue and is presumed to dominate during the estimated period. The high rise in the use of anticoagulants to treat these medical conditions has rocketed the growth. Nevertheless, the DVT segment is anticipated to experience fastest market growth due to radical transformation in diagnosis of DVT. At the same time, increasing demand for ideal therapeutics, growing population base, developing economies, and prevalence of several cardio-vascular diseases in the Asia-pacific region have made the province present a fleet of opportunities for the market players.

Check available discounts on this report at https://www.alliedmarketresearch.com/purchase-enquiry/1673

According to the report, the key players in the global anticoagulants market include Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc., Bayer AG, Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Pfizer, Bristol-Myers Squibb Company, Aspen Holdings, Portola Pharmaceuticals, Inc., Sanofi S.A., and GlaxoSmithKline plc. Their exclusive growth strategies to maintain their dominance in the market drive them towards success.

Read More @ https://www.prnewswire.com/news-releases/global-anticoagulants-market-expected-to-reach-43-427-million-by-2025-says-allied-market-research-823581454.html

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com